Alnylam Pharmaceuticals (ALNY) Accounts Payables (2009 - 2026)

Alnylam Pharmaceuticals has reported Accounts Payables for 18 years, with the latest figure at $126.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 30.01% year-over-year to $126.6 million; the trailing twelve-month figure through Mar 2026 stood at $126.6 million (up 30.01% YoY), and the FY2025 full-year result was $115.7 million, up 30.88% from the prior year.
• Accounts Payables for Q1 2026 stood at $126.6 million, up from $115.7 million in the prior quarter.
• The five-year high for Accounts Payables was $126.6 million in Q1 2026, with the low at $40.6 million in Q3 2022.
• Historically, Accounts Payables has averaged $80.5 million across 5 years, with a median of $74.0 million in 2024.
• The largest YoY upside for Accounts Payables was 82.0% in 2023 against a maximum downside of 43.4% in 2023.
• Alnylam Pharmaceuticals' Accounts Payables stood at $98.1 million in 2022, then plunged by 43.4% to $55.5 million in 2023, then soared by 59.25% to $88.4 million in 2024, then soared by 30.88% to $115.7 million in 2025, then grew by 9.43% to $126.6 million in 2026.
• The last three Accounts Payables figures came in at $126.6 million (Q1 2026), $115.7 million (Q4 2025), and $117.6 million (Q3 2025), per Business Quant data.